From January 2024June 2025, AOM tirzepatide initiations rose steadily (+239% cumulative increase, ~+0.01 points/month)
Past and current COAs are archived in the public COA library on this page, allowing researchers, procurement officers, and institutional review committees to audit lot history before purchase
Some experts worry that broader availability to certain peptides through compounding pharmacies could expose larger numbers of patients to therapies whose long-term safety profiles remain unclear
Patients who continue the max dose of GLP-1 therapy for extended periods (beyond the initial 1620 weeks) can experience more gradual but sustained weight loss
however, maintaining a weight-reduced state has been extremely challenging
The risk appears to be higher when supplements are taken on an empty stomach or as a single high bolus dose